A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck

Oral metronomic chemotherapy has significantly better PFS and OS than single agent platinum in the palliative setting.